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Background: Malaria is a complex disease, which varies in its epidemiology and clinical manifestation. Although
artemether-lumefantrine has been used as first-line drug for uncomplicated Plasmodium falciparum malaria in Bahir
Dar district since 2004, its efficacy has not yet been assessed. The main objective of this study was to quantify the
proportion of patients with uncomplicated falciparum malaria who were prescribed artemether-lumefantrine and
who failed treatment after a 28-day follow-up.
Methods: The research team attempted to conduct an observational cohort study on the assessment of therapeutic efficacy and
safety of artemether-lumefantrine in falciparummalaria patients aged over five years in Bahir Dar district fromMarch to July 2012.
Results:Among 130 participants in the study, 60%weremaleswith 1:5male to female ratio. Themean of asexual parasitaemia
load was 8675 parasites/μL and 96.1 % participants were free from parasitaemia at day 3. At the end of the study, 98.5 %
of participants showed adequate clinical and parasitological response of the drug. In the study, only 1.5 % of participants
were shown late parasitological failure between seventh and 14th day follow-up and 1.3 % of participants were free from
anaemia at the end of follow-up.
Conclusion: According to the research findings, artemether-lumefantrine fulfilled the inclusion criteria of WHO as first-line drug
and continues to be the drug of choice for the treatment of uncomplicated falciparum malaria. Outputs from this study should
be supported through advanced molecular techniques and blood concentration and pharmaco-vigilance of the drug.
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Malaria remains an important public health concern all
over the world. According to a World Health Organization
(WHO) report, the global incidence of the disease was 402
million in 107 malaria-endemic countries, and among
those, 57 % of cases occurred in sub-Saharan Africa [1, 2]
and 72 % of African cases were due to Plasmodium* Correspondence: yeh_kiam@yahoo.com
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publicdomain/zero/1.0/) applies to the data madfalciparum [3]. According to the Ethiopian Ministry of
Health Report 2011, malaria caused 14 % outpatients and
9 % health facility admissions in 2009/2010 [4, 5].
Artemether-lumefantrine (Coartem®) (AL) is a widely
accepted artemisinin-based combination therapy (ACT)
due to the emergence of resistance to previously com-
monly used drugs, such as chloroquine and sulphadoxine-
pyrimethamine [6–10]. After the implementation of AL as
the drug of choice, a radical reduction in malaria cases oc-
curred in most African countries: Rwanda (64 %), Zambia
(29 %) and Ghana (13 %) between 2000 and 2007 [11, 12].ticle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
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2004 and the disease morbidity and mortality rate de-
creased by 60 and 51 %, respectively, in 2005 and 2007 [13].
According to WHO criteria, approval of any anti-
malarial drug as a first-line drug, it should have 90 %
and above parasitological and clinical curative rates [13].
Many studies have indicated that AL is a drug which ful-
fills WHO requirements of a drug of choice for the
treatment of uncomplicated malaria [14, 15]. However,
studies conducted in Zanzibar, Thailand and Japan show
treatment failure and the evolving of drug-resistant para-
site gene pfmdr1 86 N for the drug [11, 16, 17]. There-
fore, the purpose of this study was to determine the
degree to which episodes of uncomplicated falciparum
malaria, in patients age five years and above, had been
treated with a recommended anti-malarial regimen in
the area.
Methods
Study area and period
A 28-day observational cohort study was conducted on
AL treatment effectiveness and safety, according to the
2009 WHO protocol [18], in Bahir Dar district, the capital
of Amhara National Regional State, from March to July
2012. The city is located in northwest Ethiopia, 578 km
from Addis Ababa. According to the Ethiopian Central
Statistics Agency Report, total population of the city was
180,094, of which 87,089 were males [19]. In the area mal-
aria is one of the ten top diseases and shows seasonal vari-
ation: high malaria cases are registered from September to
December (end of summer) and from May to June (begin-
ning of summer) every year [4].
Recruiting of study participants
In the study 778 febrile cases screened for signs and symp-
toms of malaria by going house to house to recruit enough
participants within a given time. Health extension workers
and clinical nurses were mobilized to recruit febrile patients
(patients with body temperature ≥37.5 °C), who were sent
to the nearby health centre (Bahir Dar Han Health Center)
with detailed information, including code number, sex, age,
and date of recruitment. Patients were re-examined at the
health centre for malaria symptoms, body temperature and
weight. Screened individuals were sent to the laboratory de-
partment for blood film and haemoglobin determination.
All laboratory procedures and tests were carried out by ex-
perienced laboratory technicians and blood collection was
done aseptically. Patients who were Plasmodium positive
and met the enrolment criteria, with full consent, were con-
sidered study participants.
Treatment and follow-up
Six doses of AL (Coartem®, 20 mg artemether/120 mg
lumefantrine) tablets were given for all study participants:who were positive for P. falciparum mono-infection; were
five years or older and able to swallow the drug; who did
not have severe acute malnutrition; had initial parasite
densities between 1000 and 100,000 parasites/μl; had no
other signs of severe and complicated falciparum malaria
(i.e., impaired consciousness, respiratory distress, multiple
convulsions, circulatory collapse, pulmonary oedema, ab-
normal bleeding, jaundice and haemoglobinurea); who
took no anti-malarial drugs prior to the beginning of the
study; and, had signed the consent form.
Drug administration
Three days of drug were administered at the health centre
based on age/body weight, under direct supervision of the
research team, and participants were observed for at least
30 min for the presence of vomiting. Patients who vom-
ited were retreated and re-observed for another 30 min,
and if they were vomited again they were excluded and re-
ferred to the local hospital for further management.
Appointing participants
Participants who finished their drugs properly were asked
to come to the health centre on days 3, 7, 14, 21, and 28.
When participants did not feel well, they were encouraged
to comeback at anytime for advanced care. Participants
who failed to come back to the health centre within the
fixed schedules were visited by the research team on the
same or the next day.
Laboratory procedures
Two senior microscopists from Han Health Centre and
one from Amhara Regional Laboratory personnel read
the blood films and did haemoglobin determination. Ca-
pillary blood samples were collected aseptically and la-
belled anonymously (i.e., code number, days of follow-up
and date). Thick and thin blood films were prepared at
day 0, stained with freshly prepared 10 % Giemsa stain
and examined for the loyalty of the inclusion criteria.
Thick blood films were examined on days 2, 3, 7, 14, 21,
28, or any day patients returned spontaneously. Parasite
count was done based on the number of asexual para-
sites observed against 200 leukocytes and multiplied by
40, to gain an approximate count per μl of blood. A slide
was considered negative when no parasites were seen
after examining 100 fields.
Parasite density perμlð Þ ¼
Average number of parasites counted
 6000‐8000ð Þ WBCs
Average Number of leukocytes counted
Haemoglobin value was measured based on packed cell
volume method at days 0, 14 and 28 according to WHO
2009 protocol.
Fig. 1 Details on study inclusion and follow up progress Bahir Dar district, March to July 2012. Among 778 malaria suspected and screened individuals,
134 P.f. mono-infected participants considered as eligible study subjects. Of them, 4 individuals excluded from the study and 130 study participants
finished and drug efficacy and safety outcomes were drawn
Fig. 2 Demographic characters of study subjects within 28 days of follow-up, Bahir Dar district, March to July 2012. A total of 130 eligible participants, 78
(60 %) males with 1:5 male to female ratio. The majority of study subjects (32.33 %) were in age group five to 14 years and males were in the majority in
the age groups
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Table 1 Baseline characteristics of participants stratified by age and sex, Bahir Dar district, March to July 2012
Age group in yrs, (n) Sex Mean weight (kg) Average body temp. (°C) Mean Hgb (g/dl) Geo. mean of parasitic load (/μl)
5–14 (42) M 25 19.44 38.56 9.65 4959.15
F 17 21.03 38.41 10.6 7313.63
15–24 (29) M 14 44.65 38.67 7.4 6082.76
F 15 36.72 38.41 10.71 4830.22
25–34 (29) M 22 53.47 38.73 10.9 6983.98
F 7 51.57 38.97 10.74 10,606.5
35–44 (16) M 9 62.56 38.71 11.81 7502.47
F 7 51.29 38.44 11.2 10,477.14
45–54 (11) M 6 62.07 39.05 12.48 7420
F 5 48.40 39.12 11.88 14,960
55–64 (3) M 2 50.10 38.3 9.35 10,950.34
F 1 47 38.4 13.4 12,017.07
The mean weight and auxiliary temperature among 130 participants at day 0 were 40.31 kg and 38.64 ± 0.18 °C, respectively. The average geometric mean of
parasitic load and mean of haemoglobin value at day 0 were 8675.27 parasites/μL and 10.84 g/dl, respectively
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The effectiveness and safety of the drug was determined
based on WHO protocol and classified as late parasito-
logical failure, adequate response and therapeutically
safe. Individuals were categorized as anaemic when their
haemoglobin level was below 7 g/dl.
Quality assurance
Three qualified microscopists (two from Han Health
Center and one from Amhara Regional Laboratory de-
partment) read and counted parasite densities and any
discordance on parasitic load calculation was done by
averaging the two closest counts. In addition, all posi-
tives and 10 % randomly selected negative slides were
cross-checked by the Regional Laboratory personnel.
Data analysis
Data were reviewed and entered in to EPI Version 2002
statistical package and transformed and analysed by SPSS
Version 16.0 package. Obtained data were evaluated byTable 2 Efficacy outcome of AL stratified by age, Bahir Dar district, M
Outcome Age group
5–14 (42) 15–24 (29) 25–3
No. (%) No. (%) No. (
ETF 0 0 0
LCF 0 0 0
LPF 0 0 1 (0.8
ACPR 42 (100) 29 (100) 28 (9
Total analysis 42 29 29
Withdrew 2 0
Total 44 29 29
ETF Early treatment failure, LCF Late clinical failure, LPF Late parasitological failure, A
Number, % percentfrequency, Chi-square (χ2) and logistic regression analyses,
and a significance level of 5 % (α = 0.05) was established.
Ethical approval
The research was ethically cleared by the Ethical Review
Board of Jimma University and written informed consent
from each participant or guardians of under-age children
was obtained. All non-participant malaria patients were
treated accordingly.
Results
Between March and July 2012, 778 febrile cases, clinic-
ally suspected to be infected with malaria, were screened
for eligibility. Of these 164 (21.1 %) had malaria-positive
slides, 145 (18.6 %) and 11 (1.4 %) were positive P. fal-
ciparum and Plasmodium vivax, respectively, and the
rest 0.9 % positive slides with mixed infections. Among
145 P. falciparum mono-infected patients, 10 could not
be enrolled in the study due their ages and having a
parasite load below 1000 parasites/μl of blood.arch to July 2012
Total
4 (29) 35–44 (16) ≥45 (14)
%) No. (%) No. (%) No. (%)
0 0 0
0 0 0
) 0 1 (0.8) 2 (1.56)




CPR Adequate clinical and parasitological response, With withdrew, No
Fig. 3 Summary of fever and parasitic load clearances within 28 days of follow-up, Bahir Dar district, March to July 2012. The study tried to correlate the
overall febrile case reduction with the geometric mean of parasitic clearance at days 0 and 3. Fever clearance rate was insignificantly associated with
parasitic clearance (P = 0.054, 95 % CI)
Table 3 Summary of the average heamoglobin concentration
(g/dl) stratified by age
Age group (years) Total
Hgb
(g/dl)
Days 5–14 (42) 15–24 (29) 25–34 (29) 35–44 (16) ≥45 (14)
Hgb Hgb Hgb Hgb Hgb
Day 0 10.11 11.08 10.17 12.52 10.24 10.82
Day 14 10.28 10.71 10.39 12.7 12.14 11.22
Day 28 10.63 10.71 10.96 11.74 12.02 11.21
Mean haemoglobin value was increased from 10.82 g/dl at day 0 to 11.21 g/dl at
the end of the study
Hgb haemoglobin
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Fig. 1 shows, two were excluded (one took anti-malarial
drug and another denied to participate). On day 7, 132
slides from patients were examined and one person was
found to be P. falciparum positive and excluded as treat-
ment failure and treated with quinine. On day 14, 131
slides were examined and three were found positive: one
for P. falciparum and excluded as a treatment failure
after treated with chloroquine, the second and third par-
ticipants were positive for P. vivax and tuberculosis and
excluded from the study. Slides from the remaining 128
patients were examined for Day 21 and 28.
As Fig. 2 shows, majority (60 %) of participants were
males and majority of participants (32.3 %) were in age
group five to 14 years. The mean body weight and auxil-
iary temperature of participants at day 0 were 40.3 kg
and 38.6 ± 0.18 °C, respectively.
Table 1 shows that, the mean of asexual parasitaemia
among 130 participants at day 0 was 8675 parasites/μL
and 85.9 and 96.1 % participants were free from parasite
at days 2 and day 3, respectively. Interestingly, no gam-
etocyte stages were detected at day 1 and only 3 % of
participants were identified with a mean of 1800/μl gam-
etocyte stages at day 3 and cleared totally at day 7. This
study didn’t show any significant association between age
differences and parasitic clearance (P = 0.877, 95 % CI)
and only 1.5 % (2/130) of participants showed late para-
sitological failure in between the seventh and 14th day of
follow-up and at the end, 98.5 % participants showed
adequate clinical and parasitological response as Table 2
shows.
Some 98.46 % participants showed fever body temperature
(>37 °C) at day 0 which lowered to 12.13 % at day 3, how-
ever, decrease in febrile cases was insignificantly associatedwith parasitic clearance (P = 0.054, 95 % C.I) as Fig. 3
shows.
At the end of the study, the mean haemoglobin level was
increased from 10.82 g/dl to 11.21 g/dl as Table 3 shows
and 1.3 % anaemic participants became non-anaemic
(≥11 g/dl). Mean haemoglobin value was inversely corre-
lated with decline in parasitic load (R = −0.430, 95 % CI)
and the occurrence of anaemia was not associated with age
differences [X2 tab (α = 0.05,df = 4) = 6.42].
Overall, only 32 % of study participants showed com-
mon and typical types of adverse effects and the most
frequently reported adverse events were weakness/fa-
tigue and headache (15.9 %), mouth rash (14.7 %), cough
(11.5 %) and joint pain (2.6 %) and loss of appetite
(1.3 %) were the least frequent adverse effects (Table 4).
However, the presence of any side effects was statistically
insignificant with age and sex (P > 0.15, 95 % CI).
Discussion
According to WHO recommendation, selection of an anti-
malarial drug as a drug of choice, it should have 90 % and
above parasitological and clinical cure rates [13]. Since
Table 4 Percent distribution of adverse effects of AL among participants in each age group and sex, Bahir Dar district, March to July 2012
Adverse effects Sex Age group in years (%) Total
(130)5–14 (42) 15–24 (29) 25–34 (29) 35–44 (16) 45+ (14)
Weakness M 24 10 16 6 0 15.9
F 8 14 4 4 0
Headache M 24 16 20 10 0 15.9
F 12 9 0 0 0
Mouth rash M 10.4 8 15 17.4 0 14.7
F 13.0 21.7 0 4.4 0
Cough M 7.2 12.7 16. 7 0 0 11.5
F 13.1 16.7 0 0 0
Abdominal pain M 21.4 21.4 21.4 0 7.14 8.9
F 0 21.4 7.1 0 0
Sore throat M 11.3 7.1 0 5.2 0 8.9
F 21.4 15.7 0 7.1 0
Tongue Inflammation M 6.1 9.2 0 9.1 0 7.01
F 7.3 16.4 0 0 0
Joint pain M 9.8 0 0 10 0 2.6
F 0 6 0 0 0
Loss of appetite M 0 0 0 8 0 1.3
F 0 0 0 0 0
All adverse effects seen in the study were registered under FDA as the usual type side effects. In the study the most frequents were weakness and headache
followed by mouth rash. Whereas, loss of appetite and joint pains were the least among others
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been conducted and its high parasitological and clinical cu-
ratives capacity fulfills WHO selection criteria. According
to this study, total efficacy result of the drug was 98.3 %
which is in line with WHO recommendation and re-
searches conducted in Ethiopia, Thailand and elsewhere
[11, 14, 15, 20].
AL is a drug with a six- to eight-fold ability to de-
crease asexual and gametocyte stages than older anti-
malarial drugs [21, 22]. Parasitaemia was reduced by 60
and 96.1 % at days 2 and 3, respectively, and totally
cleared at day 7 of follow-up. Research conducted in
Ethiopia, Mali, Zambia, Thailand and Uganda has shown
the maximum parasitaemia clearance time was at the
seventh day of study period [11, 15, 20, 23, 24].
The observed adverse effects of AL in the study were
similar between adults and children and registered under
the food and drug administration authority (FDA). The
most common adverse events were cough, upper re-
spiratory tract inflammation and abdominal pain, which
were comparable to findings conducted in Ethiopia,
Uganda and Mali [15, 20, 23].
At the end of the study, anaemic cases decreased by
1.3 % as similar studies reported in Angola and Mali
[23, 25]. A total mean value of haemoglobin was insignifi-
cantly associated with decline of parasitic load (P > 0.05,
95 % CI), which might be due to the high prevalence ofother intestinal parasitosis in the area; it is known that an-
aemia is the most prevalent, with hookworm and other in-
testinal parasite-infected areas [26, 27].Conclusion
This finding revealed that AL is safe and effective and thus
continues to be the drug of choice for the treatment of un-
complicated falciparum malaria as first-line drug. No severe
adverse effects were recorded other than FDA registered.
The six-dose regimen of AL is safe and well tolerated drug
for the treatment of acute falciparum malaria in the area.
All stakeholders in malaria treatment and management
should have determination on promoting rational use of
medication at every step to sustain the efficacy and safety of
the drug. Post-marketing drug surveillance of AL (Coar-
tem®) should be done for monitoring and evaluation of the
quality, safety and efficacy of the drug. Further PCR-based
effectiveness studies with pharmaco-vigilance of the drug
should be undertaken, to prevent decreases in drug adher-
ence which can lead to the development of drug resistance.Abbreviations
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